Aktionsplan Alpha Tau Medical Ltd.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
| IPO date |
2021-03-08 |
| ISIN |
IL0011839383 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.alphatau.com
|
| Цена ао |
2.97 |
| Preisänderung pro Tag: |
-0.3194% (3.0999) |
| Preisänderung pro Woche: |
-0.3226% (3.1) |
| Preisänderung pro Monat: |
+10.36% (2.8) |
| Preisänderung über 3 Monate: |
+32.62% (2.33) |
| Preisänderung über sechs Monate: |
+41.74% (2.18) |
| Preisänderung pro Jahr: |
+2.66% (3.01) |
| Preisänderung über 3 Jahre: |
-68.66% (9.86) |
| Preisänderung über 5 Jahre: |
0% (3.09) |
| Preisänderung über 10 Jahre: |
0% (3.09) |
| Preisänderung seit Jahresbeginn: |
+0.6515% (3.07) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
0 |
0 |
| P/BV |
2.46 |
6 |
| P/E |
0 |
0 |
| EV/EBITDA |
-5.94 |
0 |
| Gesamt: |
|
3 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
-27.15 |
0 |
| ROE, % |
-34.52 |
0 |
| Gesamt: |
|
0 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Gesamt: |
|
0 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
-0.1928 |
10 |
| Gesamt: |
|
10 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
0 |
0 |
| Rentabilität Ebitda, % |
306.2 |
10 |
| Rentabilität EPS, % |
235.67 |
10 |
| Gesamt: |
|
8 |
|
| Institutionen |
Volumen |
Aktie, % |
| Levin Capital Strategies, LP |
330123 |
0.48 |
| Morgan Stanley |
305182 |
0.44 |
| Hoylecohen, LLC |
269088 |
0.39 |
| Corbin Capital Partners, LP |
260109 |
0.38 |
| HighTower Advisors, LLC |
212508 |
0.31 |
| Atalaya Capital Management, LP |
73742 |
0.11 |
| Satovsky Asset Management, LLC |
58430 |
0.08 |
| Private Advisor Group, LLC |
58430 |
0.08 |
| Mariner, LLC |
38584 |
0.06 |
| Geode Capital Management, LLC |
35716 |
0.05 |
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Mr. Uzi Sofer |
CEO & Chairman |
630k |
1970 (55 Jahre) |
| Mr. Raphi Levy |
Chief Financial Officer |
424k |
1985 (40 Jahre) |
| Mr. Amnon Gat |
Chief Operations Officer |
340k |
1975 (50 Jahre) |
| Mr. Ronen Segal |
Chief Technology Officer |
380k |
1973 (52 Jahr) |
| Dr. Robert B. Den M.D. |
Chief Medical Officer & Member of Scientific Advisory Board |
401k |
1979 (46 Jahre) |
| Prof. Yona Keisari |
Chief Scientific Officer & Member of Scientific Advisory board |
N/A |
1947 (78 Jahre) |
| Ms. Rebecca Becker |
Vice President of legal |
N/A |
|
| Mr. Peter M. Melnyk |
Chief Commercial Officer |
376k |
1962 (63 Jahr) |
| Prof. Itzhak Kelson |
Chief Physics Officer & Member of Scientific Advisory Board |
N/A |
1940 (85 Jahre) |
| Ms. Yael Zeiger |
Corporate Controller |
N/A |
1983 (42 Jahr) |
